Compound name
GSK046
Protein family
Bromodomain
Target name
BRD2@BD2
Affinity biochemical (nM)
251
CG-Set
Epigenetic set
Recommended Concentration
1 µM
Compound EUbOPEN ID
EUB0001114a
SMILES
CC(Nc1c(cc(cc1F)C(N[C@H]1CC[C@@H](CC1)O)=O)O[C@@H](C)c1ccccc1)=O
InChIKey
FRBRZGLUFOZRGD-JVPBZIDWSA-N
NCBI gene ID
6046
UniProt ID
P25440
Synonyms
KIAA9001, RING3, D6S113E, NAT, FSRG1
Mode of action
Inhibitor
Negative control
No control available for probe
Affinity biochemical definition
IC50
Affinity biochemical assay type
BET mutant TR-FRET assay (BD2)
Affinity Biochemical Source Knowledge
https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00605
Affinity biochemical relation
0
Selectivity platform
BROMOScan (DiscoverX)
Selectivity platform number of targets
40
Selectivity remarks
In-vitro potencies of closest targets in BROMOScan (DiscoverX): Kd(BRD2, BD1) = 1621 nM, Kd(BRD2, BD2) = 35 nM (64-fold selective), Kd(BRD3, BD1) = 2082 nM, Kd(BRD3, BD2) = 32 nM (63-fold selective), Kd(BRD4, BD1) = 769 nM, Kd(BRD4, BD2) = 9 nM (85-fold selective), Kd(BRDT, BD1) = 2454 nM, Kd(BRDT, BD2) = 15 nM (164-fold selective); In-vitro potencies (SPR measurements): Kd(BRD4, BD1) >10 µM, Kd(BRD4, BD2) = 30 nM, excellent selectivity against other BCPs, Kd >30 µM for TAF1(BD2), BRD9, TAF1L(BD2), BAZ2A, CECR2, BAZ2B; Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potency of closest target: Ki(HTR1D) = 3438.75 nM
Selectivity Source Knowledge
https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00605
Selectivity Number of Off-targets
0